Chemomab Therapeutics (2QV) Stock Price & Analysis

2QV Stock Chart & Stats

€2.94€0.00(0.00%)

At close: Nov 02 5:30 PM GMT+1

Day’s Range: EUR 2.94 - EUR 3.14
52-Week Range: EUR 2.94 - EUR 3.14
Previous Close: EUR 2.94
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 7.51M
Enterprise Value: EUR 6.28M
Total Cash (Recent Filing): EUR 6.69M
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: 0.52
Next Earnings: Nov 06, 2026 (Est.)
EPS Estimate: 0
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Minimal Leverage

Very low leverage reduces fixed financial obligations and preserves flexibility while the company advances clinical programs. A lightly indebted balance sheet may make it easier to allocate future capital toward research and development rather than interest payments, although losses remain material.

Improving Loss And Burn Profile

The improvement in annual losses and cash burn indicates some expense discipline within the early-stage operating model. If sustained, better cost control could extend available resources and reduce the pace of external funding needed while clinical development continues.

Focused Clinical Pipeline

A concentrated pipeline around CCL24 and fibro-inflammatory diseases gives Chemomab a clear development focus rather than a broad, unfocused portfolio. This specialization can support efficient research prioritization and consistent scientific positioning as programs advance.

Bears Say

Pre-Revenue Operating Model

Continued absence of revenue means Chemomab has not yet demonstrated commercial traction or an operating model capable of funding itself. The company therefore remains dependent on successful clinical progress and eventual commercialization to establish sustainable earnings.

Persistent Cash Burn

Persistent negative operating and free cash flow limits financial independence and makes future development reliant on additional capital. Even with improved 2025 burn, financing needs can constrain program choices and increase vulnerability if funding conditions become less favorable.

Transaction Execution Risk

The proposed redomiciliation and Scipher merger could materially reshape Chemomab, but completion depends on regulatory approvals, shareholder action, financing, and other execution steps. Delays or failure would disrupt the planned strategic path and add uncertainty to development funding.

Chemomab Therapeutics News

Chemomab Restructures Into U.S. Parent Ahead of Merger With Scipher

New activity is brewing for Chemomab Therapeutics ( ($CMMB) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all

3d agoCMMB 2QV

Chemomab Tightens Share Structure in U.S. Redomiciliation Ahead of Scipher Merger

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. On October 16, 2026, Chemomab Therapeutics, its Delaware holding entity Snowdrift Parent Corporation and Israeli subsidiary Elderwood Ltd. signed a second

2w ago6K CMMB

Chemomab Refines Share Structure in Domestication Deal Ahead of Scipher Merger

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. On September 23, 2026, Chemomab Therapeutics and its subsidiaries executed Amendment No. 1 to their domestication merger agreement tied to the

1M ago6K CMMB

Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations

Chemomab Therapeutics ( ($CMMB) ) has issued an update. On August 19, 2026, Chemomab Therapeutics filed a Form 6‑K with the U.S. Securities and Exchange Commission, reporting unaudited condensed consolidated

2M ago6K CMMB

Chemomab Therapeutics and Scipher Medicine to Merge in AI‑Driven Rheumatoid Arthritis Play

Chemomab Therapeutics ( ($CMMB) ) has issued an update. On July 7–8, 2026, Chemomab Therapeutics and Scipher Medicine entered into a definitive stock‑for‑stock merger agreement that will redomicile Chemomab to

3M ago6K CMMB

Chemomab Therapeutics, Scipher Medicine announce merger agreement

Chemomab Therapeutics (CMMB) and Scipher Medicine announced that they have entered into a definitive merger agreement pursuant to which the companies will combine in a stock transaction. Upon completion of

3M agoCMMB 2QV

Chemomab Therapeutics Revamps Board and Committees With New Independent Director

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. On June 1, 2026, Chemomab Therapeutics’ board appointed veteran biotech dealmaker Gwen Melincoff as a Class I director and chair of

5M ago6K CMMB

Okunewitch Reiterates Buy on Emerging Nebokitug Data and Solid Cash Runway; Price Target Maintained at $5

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Chemomab Therapeutics. The associated price target remains the same with $5.00. Michael Okunewitch has given his Buy rating

5M agoCMMB 2QV

Chemomab Highlights New Nebokitug Data in PSC as Q1 2026 Update Underscores PSC–IBD Potential

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. On May 14, 2026, Chemomab reported first-quarter 2026 results and a corporate update centered on new clinical and translational data for

5M ago6K CMMB

Chemomab Shareholders Approve Governance Resolutions and Capital Increase at May 5 Meeting

Chemomab Therapeutics ( ($CMMB) ) has shared an update. On May 5, 2026, Chemomab Therapeutics held its adjourned annual general shareholders meeting in Ramat Gan, Israel, where investors approved key

6M ago6K CMMB

Chemomab Adjourns April 28 Shareholder Meeting to May 5 After Quorum Shortfall

Chemomab Therapeutics ( ($CMMB) ) has provided an announcement. Chemomab Therapeutics announced that its Annual General Meeting of Shareholders, originally scheduled for April 28, 2026 in Ramat Gan, Israel, was

6M ago6K CMMB

Chemomab Therapeutics sees cash runway through 1Q27

Cash, cash equivalents and short-term bank deposits were $10.4 million as of December 31, 2025 compared to $14.3 million as of December 31, 2024. The current cash runway is expected

7M agoCMMB 2QV

Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year

“2025 was a critical year for Chemomab and our nebokitug program,” said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. “Our Phase 2 SPRING trial data, viewed by

7M agoCMMB 2QV

Chemomab Therapeutics announces results of its Phase 2 SPRING trial

Chemomab Therapeutics (CMMB) announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis, PSC, were published in the current issue of the

11M agoCMMB 2QV

2QV FAQ

What was Chemomab Therapeutics’s price range in the past 12 months?

Chemomab Therapeutics lowest stock price was €2.94 and its highest was €3.14 in the past 12 months.

What is Chemomab Therapeutics’s market cap?

Chemomab Therapeutics’s market cap is €7.51M.

When is Chemomab Therapeutics’s upcoming earnings report date?

Chemomab Therapeutics’s next earnings report is estimated for Nov 06, 2026 (not yet confirmed), which is in 3 days.

How were Chemomab Therapeutics’s earnings last quarter?

Chemomab Therapeutics released its earnings results on Aug 19, 2026. The company reported -€0.003 earnings per share for the quarter, beating the consensus estimate of -€0.134 by €0.131.

Is Chemomab Therapeutics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Chemomab Therapeutics pay dividends?

Chemomab Therapeutics does not currently pay dividends.

What is Chemomab Therapeutics’s EPS estimate?

Chemomab Therapeutics’s EPS estimate is 0.00.

How many shares outstanding does Chemomab Therapeutics have?

Chemomab Therapeutics has 7,200,378 shares outstanding.

What happened to Chemomab Therapeutics’s price movement after its last earnings report?

Chemomab Therapeutics reported an EPS of -€0.003 in its last earnings report, beating expectations of -€0.134. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Chemomab Therapeutics?

Currently, no hedge funds are holding shares in DE:2QV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description